Potentially game changing therapeutic concepts
Video: A short introduction to EVOgenes
EVOgenes – from MARKET entry to fully developed platform
With the expansion into gene therapy in 2020, Evotec added an important emerging modality to its portfolio. The establishment of a dedicated site for research and development of gene therapy-based projects in Orth/Donau, Austria, marked a significant step towards Evotec’s long-term vision of becoming a fully modality-agnostic drug discovery and development partnership company.
Gene therapy is a technology that delivers the therapeutic genetic material either through ex-vivo modified cells or directly into a patient’s body. Due to recent progression in this field coupled with the vast future potential, gene therapy is indisputably one of the most exciting and fastest growing areas of biotechnology at this moment. Techniques such as AAV (adeno-associated virus) and lentiviral gene transfer, as well as the increasingly important area of RNA technologies, open up therapeutic options to potentially address and modify complex biologic issues in a unique and novel way.
In fact, it is predicted that the size of the gene therapy market, combined with its sister technology, cell therapy, will grow at a CAGR of 26%. More importantly, a variety of so far untreatable diseases can be addressed only by gene therapy products.
The team developing the EVOgenes platform has deep expertise in rare genetic disease drug development. This expertise paired with the opportunity to leverage and fully exploit the breadth of experience and capabilities of the wider Evotec network, including biomarker and analytical capabilities, is the path to success.
The team will grow fast and significantly, thus enabling the achievement of its goal, to establish a fully developed gene therapy platform that will allow
- a broad gene therapy offering for clients including proprietary platform technology
- employment of artificial intelligence and machine learning
- the advantage of a strong IP position to drive programme co-ownership and enriched deal terms